Phase II Trial of ILX295501 Administered Orally Once Weekly x 3 Repeated Every 6 Weeks in Patients With Stage III/IV Ovarian Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
At a glance
- Drugs ILX 295501 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 16 Sep 2018 Status changed to withdrawn prior to enrolment.
- 17 Sep 2005 New trial record.